摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,2,3,4-Tetrahydro-3-methyl-2-oxo-1,8-naphthyridin | 40000-80-4

中文名称
——
中文别名
——
英文名称
1,2,3,4-Tetrahydro-3-methyl-2-oxo-1,8-naphthyridin
英文别名
3-methyl-3,4-dihydro-1H-[1,8]naphthyridin-2-one;3-methyl-3,4-dihydro-1H-1,8-naphthyridin-2-one
1,2,3,4-Tetrahydro-3-methyl-2-oxo-1,8-naphthyridin化学式
CAS
40000-80-4
化学式
C9H10N2O
mdl
——
分子量
162.191
InChiKey
SHLRYTOPHUYTIS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • [EN] TETRAHYDROQUINOLONES AND AZA-ANALOGUES THEREOF FOR USE AS DPP-IV INHIBITORS IN THE TREATEMENT OF DIABETES<br/>[FR] TETRAHYDROQUINOLONES ET AZA-ANALOGUES ASSOCIES UTILISES EN TANT QU'INHIBITEURS DE LA DPP-IV DANS LE TRAITEMENT DU DIABETE
    申请人:ASTRAZENECA AB
    公开号:WO2005123685A1
    公开(公告)日:2005-12-29
    Compound of formula (I) or a pharmaceutically-acceptable salt thereof, formula (I) wherein Ar is optionally substituted phenyl; R1 is selected from: formula a) or b) (wherein is a single or double bond); R5, R6, R7 and R8 are for example hydrogen or alkyl; R4 is selected from hydrogen, (3-4C)cycloalkyl and optionally substituted (1-4C)alkyl; R10 is for example selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl, hydroxy(1-4C)alkyl, (1-4C)alkoxy, aryl(1-4C)alkyl; Y is carbon and Ring A is optionally substituted phenylene; or each Y may independently be carbon or nitrogen and Ring A is optionally substituted 5- or 6-membered, heteroarylene ring; R11 is selected from hydrogen and optionally substituted phenyl; p is independently at each occurrence 0, 1 or 2; are described. Processes for making such compounds and their use as DPP-IV inhibitors in the treatment of diabetes are also described.
    化合物的化学式(I)或其药用可接受的盐,其中化学式(I)中Ar是可选择的取代苯基;R1选自:化学式a)或b)(其中是单键或双键);R5、R6、R7和R8例如是氢或烷基;R4选自氢、(3-4C)环烷基和可选择的取代(1-4C)烷基;R10例如选自氢、(1-4C)烷基、(3-6C)环烷基(1-4C)烷基、羟基(1-4C)烷基、(1-4C)烷氧基、芳基(1-4C)烷基;Y是碳,环A是可选择的取代苯基;或每个Y可以独立地是碳或氮,环A是可选择的取代的5-或6-成员的杂芳烃环;R11选自氢和可选择的取代苯基;p在每次出现时独立地为0、1或2;描述了制备这类化合物的过程以及它们作为DPP-IV抑制剂在糖尿病治疗中的用途。
  • Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes
    申请人:Birch Martin Alan
    公开号:US20080009512A1
    公开(公告)日:2008-01-10
    Compound of formula (I) or a pharmaceutically-acceptable salt thereof, formula (I) wherein Ar is optionally substituted phenyl; R 1 is selected from: formula a) or b) (wherein is a single or double bond); R 5 , R 6 , R 7 and R 8 are for or alkyl; R 4 is selected from hydrogen, (3-4C)cycloalkyl and optionally substituted (1-4C)alkyl; R 10 is for example selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl(1-4C)alkyl, hydroxy(1-4C)alkyl, (1-4C)alkoxy, aryl(1-4C)alkyl; Y is carbon and Ring A is optionally substituted phenylene; or each Y may independently be carbon or nitrogen and Ring A is optionally substituted 5- or 6-membered, heteroarylene ring; R 11 is selected from hydrogen and optionally substituted phenyl; p is independently at each occurrence 0, 1 or 2; are described. Processes for making such compounds and their use as DPP-IV inhibitors in the treatment of diabetes are also described.
    化合物的公式(I)或其药学上可接受的盐,公式(I)中 Ar 是可选的取代苯基;R1 选自:公式 a)或 b)(其中是单键或双键);R5、R6、R7 和 R8 是氢或烷基;R4 选自氢、(3-4C)环烷基和可选取代的(1-4C)烷基;R10 例如选自氢、(1-4C)烷基、(3-6C)环烷基(1-4C)烷基、羟基(1-4C)烷基、(1-4C)烷氧基、芳基(1-4C)烷基;Y 是碳且环A是可选的取代苯基;或每个Y可以独立地是碳或氮,环A是可选的取代5-或6-成员的杂环芳烃环;R11选自氢和可选取代的苯基;p 在每次出现时独立地为0、1或2。描述了制备这种化合物的过程以及它们作为DPP-IV抑制剂在糖尿病治疗中的用途。
查看更多